Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC
Status:
Terminated
Trial end date:
2017-09-27
Target enrollment:
Participant gender:
Summary
This is a prospective, single institution phase II study, whose primary objective is to
estimate the median and three year survival rate of non-small lung cancer patients with Stage
IIIA and IIIB intra-thoracic disease which is referred to as "locally advanced" non-small
cell lung cancer (NSCLC).